Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer

Maarit K. Koivisto, Minna Tervahartiala, I. Kenessey, Sirpa Jalkanen, Peter J. Boström, Marko Salmi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

CD73 is an adenosine-producing cell surface enzyme, which exerts strong anti-inflammatory and migration modulating effects in many cell types. We evaluated the potential of CD73 as a biomarker in predicting the outcome of bladder carcinoma. CD73 expression in tumor and stromal cells was analyzed using immunohistochemistry in 270 bladder cancer (BC) patients [166 non-muscle-invasive BC (NMIBC) and 104 muscle-invasive BC (MIBC) tumors]. The correlations of CD73 with clinical and pathological characteristics were evaluated with Pearson's and Fischer's tests. The Kaplan-Meier method and Cox proportional hazards regression models were used to analyze the association between CD73 expression and outcome. CD73 expression showed substantial variation in basal and suprabasal layers of the cancerous epithelium, stromal fibroblasts, endothelial cells and lymphocytes in different tumor specimens. In log-rank analyses, CD73 expression in cancer cells associated with better survival both in NMIBC and MIBC, whereas CD73 positivity in stromal fibroblasts associated with impaired survival in NMIBC. In multivariable models, CD73 negative epithelial cells in both BC types and CD73 negative endothelial cells in MIBC were independent factors predicting poor outcome. We conclude that in contrast to many other cancer types, high CD73 expression in BC predicts favorable prognosis.

Original languageEnglish
Pages (from-to)84-92
Number of pages9
JournalCarcinogenesis
Volume40
Issue number1
DOIs
Publication statusPublished - Mar 12 2019

Fingerprint

Urinary Bladder Neoplasms
Neoplasms
Endothelial Cells
Muscle Neoplasms
Fibroblasts
Muscles
Survival
Stromal Cells
Proportional Hazards Models
Adenosine
Urinary Bladder
Anti-Inflammatory Agents
Epithelium
Biomarkers
Epithelial Cells
Immunohistochemistry
Lymphocytes
Carcinoma
Enzymes

ASJC Scopus subject areas

  • Cancer Research

Cite this

Koivisto, M. K., Tervahartiala, M., Kenessey, I., Jalkanen, S., Boström, P. J., & Salmi, M. (2019). Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. Carcinogenesis, 40(1), 84-92. https://doi.org/10.1093/carcin/bgy154

Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. / Koivisto, Maarit K.; Tervahartiala, Minna; Kenessey, I.; Jalkanen, Sirpa; Boström, Peter J.; Salmi, Marko.

In: Carcinogenesis, Vol. 40, No. 1, 12.03.2019, p. 84-92.

Research output: Contribution to journalArticle

Koivisto, MK, Tervahartiala, M, Kenessey, I, Jalkanen, S, Boström, PJ & Salmi, M 2019, 'Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer', Carcinogenesis, vol. 40, no. 1, pp. 84-92. https://doi.org/10.1093/carcin/bgy154
Koivisto, Maarit K. ; Tervahartiala, Minna ; Kenessey, I. ; Jalkanen, Sirpa ; Boström, Peter J. ; Salmi, Marko. / Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. In: Carcinogenesis. 2019 ; Vol. 40, No. 1. pp. 84-92.
@article{4c02e7397c4b4778bbe340b37515699b,
title = "Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer",
abstract = "CD73 is an adenosine-producing cell surface enzyme, which exerts strong anti-inflammatory and migration modulating effects in many cell types. We evaluated the potential of CD73 as a biomarker in predicting the outcome of bladder carcinoma. CD73 expression in tumor and stromal cells was analyzed using immunohistochemistry in 270 bladder cancer (BC) patients [166 non-muscle-invasive BC (NMIBC) and 104 muscle-invasive BC (MIBC) tumors]. The correlations of CD73 with clinical and pathological characteristics were evaluated with Pearson's and Fischer's tests. The Kaplan-Meier method and Cox proportional hazards regression models were used to analyze the association between CD73 expression and outcome. CD73 expression showed substantial variation in basal and suprabasal layers of the cancerous epithelium, stromal fibroblasts, endothelial cells and lymphocytes in different tumor specimens. In log-rank analyses, CD73 expression in cancer cells associated with better survival both in NMIBC and MIBC, whereas CD73 positivity in stromal fibroblasts associated with impaired survival in NMIBC. In multivariable models, CD73 negative epithelial cells in both BC types and CD73 negative endothelial cells in MIBC were independent factors predicting poor outcome. We conclude that in contrast to many other cancer types, high CD73 expression in BC predicts favorable prognosis.",
author = "Koivisto, {Maarit K.} and Minna Tervahartiala and I. Kenessey and Sirpa Jalkanen and Bostr{\"o}m, {Peter J.} and Marko Salmi",
year = "2019",
month = "3",
day = "12",
doi = "10.1093/carcin/bgy154",
language = "English",
volume = "40",
pages = "84--92",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer

AU - Koivisto, Maarit K.

AU - Tervahartiala, Minna

AU - Kenessey, I.

AU - Jalkanen, Sirpa

AU - Boström, Peter J.

AU - Salmi, Marko

PY - 2019/3/12

Y1 - 2019/3/12

N2 - CD73 is an adenosine-producing cell surface enzyme, which exerts strong anti-inflammatory and migration modulating effects in many cell types. We evaluated the potential of CD73 as a biomarker in predicting the outcome of bladder carcinoma. CD73 expression in tumor and stromal cells was analyzed using immunohistochemistry in 270 bladder cancer (BC) patients [166 non-muscle-invasive BC (NMIBC) and 104 muscle-invasive BC (MIBC) tumors]. The correlations of CD73 with clinical and pathological characteristics were evaluated with Pearson's and Fischer's tests. The Kaplan-Meier method and Cox proportional hazards regression models were used to analyze the association between CD73 expression and outcome. CD73 expression showed substantial variation in basal and suprabasal layers of the cancerous epithelium, stromal fibroblasts, endothelial cells and lymphocytes in different tumor specimens. In log-rank analyses, CD73 expression in cancer cells associated with better survival both in NMIBC and MIBC, whereas CD73 positivity in stromal fibroblasts associated with impaired survival in NMIBC. In multivariable models, CD73 negative epithelial cells in both BC types and CD73 negative endothelial cells in MIBC were independent factors predicting poor outcome. We conclude that in contrast to many other cancer types, high CD73 expression in BC predicts favorable prognosis.

AB - CD73 is an adenosine-producing cell surface enzyme, which exerts strong anti-inflammatory and migration modulating effects in many cell types. We evaluated the potential of CD73 as a biomarker in predicting the outcome of bladder carcinoma. CD73 expression in tumor and stromal cells was analyzed using immunohistochemistry in 270 bladder cancer (BC) patients [166 non-muscle-invasive BC (NMIBC) and 104 muscle-invasive BC (MIBC) tumors]. The correlations of CD73 with clinical and pathological characteristics were evaluated with Pearson's and Fischer's tests. The Kaplan-Meier method and Cox proportional hazards regression models were used to analyze the association between CD73 expression and outcome. CD73 expression showed substantial variation in basal and suprabasal layers of the cancerous epithelium, stromal fibroblasts, endothelial cells and lymphocytes in different tumor specimens. In log-rank analyses, CD73 expression in cancer cells associated with better survival both in NMIBC and MIBC, whereas CD73 positivity in stromal fibroblasts associated with impaired survival in NMIBC. In multivariable models, CD73 negative epithelial cells in both BC types and CD73 negative endothelial cells in MIBC were independent factors predicting poor outcome. We conclude that in contrast to many other cancer types, high CD73 expression in BC predicts favorable prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85062842032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062842032&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgy154

DO - 10.1093/carcin/bgy154

M3 - Article

C2 - 30395172

AN - SCOPUS:85062842032

VL - 40

SP - 84

EP - 92

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 1

ER -